Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade

Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies

(2015) C. Drechsler et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

(2015)   LANCET

Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy

(2015) Luis M. Ruilope et al.   AMERICAN JOURNAL OF NEPHROLOGY

A1.72 Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study1

(2014) Peter Taylor et al.   ANNALS OF THE RHEUMATIC DISEASES

Ask1Gene Deletion Blocks Maternal Diabetes–Induced Endoplasmic Reticulum Stress in the Developing Embryo by Disrupting the Unfolded Protein Response Signalosome

(2014) Fang Wang et al.   DIABETES

Blocking Ligand Occupancy of the αVβ3 Integrin Inhibits the Development of Nephropathy in Diabetic Pigs

(2014) Laura A. Maile et al.   ENDOCRINOLOGY

Apoptosis signal-regulating kinase 1 as a therapeutic target

(2014) Yosuke Kawarazaki et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality

(2014) Josef Coresh et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Quantitative analyses of CTP-499 and five major metabolites by core-structure analysis

(2014) Xiaonan Tang et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy

(2014) D. de Zeeuw et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Effect of Pentoxifylline on Renal Function and Urinary Albumin Excretion in Patients with Diabetic Kidney Disease: The PREDIAN Trial

(2014) J. F. Navarro-Gonzalez et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Sphingomyelinase-Like Phosphodiesterase 3b Expression Levels Determine Podocyte Injury Phenotypes in Glomerular Disease

(2014) T.-H. Yoo et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Antibodies to watch in 2015

(2014) Janice M Reichert   mAbs

Therapeutic approaches to diabetic nephropathy—beyond the RAS

(2014) Beatriz Fernandez-Fernandez et al.   Nature Reviews Nephrology

Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy

(2014) Justyna Siwy et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study

(2014) Tatsuo Hosoya et al.   Trials

Mineralocorticoid receptor antagonists: part of an emerging treatment paradigm for chronic kidney disease

(2014) Murray Epstein   Lancet Diabetes & Endocrinology

Involvement of ASK1–p38 pathway in the pathogenesis of diabetes triggered by pancreatic ß cell exhaustion

(2013) Kiyoshi Yamaguchi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Uric Acid Lowering to Prevent Kidney Function Loss in Diabetes: The Preventing Early Renal Function Loss (PERL) Allopurinol Study

(2013) David M. Maahs et al.   Current Diabetes Reports

Renal Structure in Normoalbuminuric and Albuminuric Patients With Type 2 Diabetes and Impaired Renal Function

(2013) E. I. Ekinci et al.   DIABETES CARE

Standards of Medical Care in Diabetes--2014

(2013)   DIABETES CARE

Diabetic nephropathy: are there new and potentially promising therapies targeting oxygen biology?

(2013) Toshio Miyata et al.   KIDNEY INTERNATIONAL

Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease

(2013) Stacey Ruiz et al.   KIDNEY INTERNATIONAL

Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes

(2013) Timothy J. Sullivan et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Cell–matrix adhesion of podocytes in physiology and disease

(2013) Norman Sachs et al.   Nature Reviews Nephrology

Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy

(2013) Linda F. Fried et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

(2013) Dick de Zeeuw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Oral Paricalcitol on Secondary Hyperparathyroidism and Proteinuria of Kidney Transplant Patients

(2013) Esther Gonzalez et al.   TRANSPLANTATION

Advanced Diabetic Nephropathy with Nephrotic Range Proteinuria: A Pilot Study of the Long-Term Efficacy of Subcutaneous ACTH Gel on Proteinuria, Progression of CKD, and Urinary Levels of VEGF and MCP-1

(2013) J. A. Tumlin et al.   Journal of Diabetes Research

Bindarit

(2012) Eugenio Mora et al.   CELL CYCLE

AG490 Promotes HIF-1α Accumulation by Inhibiting Its Hydroxylation

(2012) R. Fernandez-Sanchez et al.   CURRENT MEDICINAL CHEMISTRY

Evaluation of the effectiveness of sarpogrelate on the surrogate markers for macrovascular complications in patients with type 2 diabetes

(2012) So Young Park et al.   ENDOCRINE JOURNAL

Targeting chemokines in proteinuria-induced renal disease

(2012) Juan Antonio Moreno et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

One Target—Two Different Binding Modes: Structural Insights into Gevokizumab and Canakinumab Interactions to Interleukin-1β

(2012) Michaela Blech et al.   JOURNAL OF MOLECULAR BIOLOGY

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tubular Atrophy and Interstitial Fibrosis After Renal Transplantation Is Dependent on Galectin-3

(2012) Zexu Dang et al.   TRANSPLANTATION

Sulodexide for Kidney Protection in Type 2 Diabetes Patients With Microalbuminuria: A Randomized Controlled Trial

(2011) Edmund J. Lewis et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Aldosterone-Induced Fibrosis in the Kidney: Questions and Controversies

(2011) Andrew S. Brem et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Antiproteinuric Effect of Chemokine C-C Motif Ligand 2 Inhibition in Subjects with Acute Proliferative Lupus Nephritis

(2011) Alessandro Ble et al.   AMERICAN JOURNAL OF NEPHROLOGY

Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and MicroalbuminuriaAn Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications CohortMicroalbuminuria Outcomes in Type 1 Diabetes

(2011) Ian H. de Boer   ARCHIVES OF INTERNAL MEDICINE

Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States

(2011) Ian H. de Boer   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy

(2011) D. E. Kohan et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Pyridorin in Type 2 Diabetic Nephropathy

(2011) E. J. Lewis et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes

(2011) Sufyan G. Sayyed et al.   KIDNEY INTERNATIONAL

Paricalcitol for reduction of albuminuria in diabetes

(2011) Alberto Ortiz et al.   LANCET

Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

(2011) Pablo E. Pergola et al.   NEW ENGLAND JOURNAL OF MEDICINE

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

(2011) Hermann Haller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

(2010) Rudolf A. de Boer et al.   ANNALS OF MEDICINE

Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk

(2010) M. Goicoechea et al.   Clinical Journal of the American Society of Nephrology

Development and Progression of Renal Insufficiency With and Without Albuminuria in Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study

(2010) M. E. Molitch et al.   DIABETES CARE

High-Normal Serum Uric Acid Increases Risk of Early Progressive Renal Function Loss in Type 1 Diabetes: Results of a 6-year follow-up

(2010) L. H. Ficociello et al.   DIABETES CARE

Pentoxifylline for Renoprotection in Diabetic Nephropathy: the PREDIAN study. Rationale and basal results

(2010) Juan F. Navarro-González et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

BASP1 Promotes Apoptosis in Diabetic Nephropathy

(2010) M. D. Sanchez-Nino et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

NF- B in Renal Inflammation

(2010) A. B. Sanz et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Suppressors of Cytokine Signaling Abrogate Diabetic Nephropathy

(2010) G. Ortiz-Munoz et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Avosentan for Overt Diabetic Nephropathy

(2010) J. F.E. Mann et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

(2010) Dick de Zeeuw et al.   LANCET

Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy

(2010) M. D. Sanchez-Nino et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Oral Paricalcitol in the Treatment of Patients With CKD and Proteinuria: A Randomized Trial

(2009) Steven Fishbane et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

The roles of ASK family proteins in stress responses and diseases

(2009) Kazuki Hattori et al.   Cell Communication and Signaling

Galectin-3 Expression and Secretion Links Macrophages to the Promotion of Renal Fibrosis

(2008) Neil C. Henderson et al.   AMERICAN JOURNAL OF PATHOLOGY

Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy

(2008) Shinya Kobayashi et al.   Clinical and Experimental Nephrology

Enhanced Expression of Janus Kinase-Signal Transducer and Activator of Transcription Pathway Members in Human Diabetic Nephropathy

(2008) C. C. Berthier et al.   DIABETES

Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney Disease

(2008) Pooneh Alborzi et al.   HYPERTENSION

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

(2008) Johannes FE Mann et al.   LANCET

A Role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury

(2008) Ana Paula Fernandes Bertocchi et al.   TRANSPLANT INTERNATIONAL